Further clarification regarding these mechanisms of action would provide better insight into TRAIL sensitivity and might provide novel therapeutic targets to reverse TRAIL resistance in NSCLC; (4) BID seems to be a major factor contributing to TRAIL-induced apoptosis with more influence than Bcl-2 and Mcl-1. Here, BCL2 is linked to non-small cell lung carcinoma.